amphetamines and other stimulants history
... Every drug in the amphetamine group is a psychostimulant (a drug that increases the activity of the brain). Unlike many other frequently abused drugs, amphetamines are not natural, but can only be made in a chemical laboratory (Lukas, 1989, p. 9). Amphetamines were originally made in 1887 by a Germa ...
... Every drug in the amphetamine group is a psychostimulant (a drug that increases the activity of the brain). Unlike many other frequently abused drugs, amphetamines are not natural, but can only be made in a chemical laboratory (Lukas, 1989, p. 9). Amphetamines were originally made in 1887 by a Germa ...
full prescribing information
... 26-week trial was conducted in 1110 patients with perennial allergic rhinitis [394 (35.5%) males and 716 (64.5%) females, ages 12 to 78 years old] treated with ZETONNA 74 mcg, 148 mcg or placebo once daily. Of these patients, 298 were treated with 74 mcg ZETONNA, 505 with 148 mcg, and 307 with place ...
... 26-week trial was conducted in 1110 patients with perennial allergic rhinitis [394 (35.5%) males and 716 (64.5%) females, ages 12 to 78 years old] treated with ZETONNA 74 mcg, 148 mcg or placebo once daily. Of these patients, 298 were treated with 74 mcg ZETONNA, 505 with 148 mcg, and 307 with place ...
How I treat with anticoagulants in 2012: new and old
... interest policy. The guideline provides a class I, level of evidence B recommendation for dabigatran as an agent to prevent stroke in patients with atrial fibrillation. However, the guideline notes, “Because of the twice daily dosing and greater risk of nonhemorrhagic side effects … patients already ...
... interest policy. The guideline provides a class I, level of evidence B recommendation for dabigatran as an agent to prevent stroke in patients with atrial fibrillation. However, the guideline notes, “Because of the twice daily dosing and greater risk of nonhemorrhagic side effects … patients already ...
Medication Administration
... • NEVER crush sustained release, controlled release or enteric coated pills. • Capsules can not be split • More than 3 to = dose • Place into plastic/paper administration cup without touching the med. • May use pudding or applesauce for patient’s with difficulty swallowing • Stay with patient until ...
... • NEVER crush sustained release, controlled release or enteric coated pills. • Capsules can not be split • More than 3 to = dose • Place into plastic/paper administration cup without touching the med. • May use pudding or applesauce for patient’s with difficulty swallowing • Stay with patient until ...
Media Kit - Perosphere Inc.
... PER977 is currently undergoing Phase 2 clinical trials in the United States. A New Drug Application (NDA) submission to the United States Food and Drug Administration (FDA) is anticipated in 2015, followed by submissions to the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical ...
... PER977 is currently undergoing Phase 2 clinical trials in the United States. A New Drug Application (NDA) submission to the United States Food and Drug Administration (FDA) is anticipated in 2015, followed by submissions to the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical ...
Visions 4.2 - Medications
... never knew him, but my granduncle was institutionalized for ‘melancholia’ in the 1920s or 30s. His depression left him catatonic toward the end of his life and he never left that facility. When, 75 years later, I needed psychotropic medication as part of my treatment plan, I thought of him whenever ...
... never knew him, but my granduncle was institutionalized for ‘melancholia’ in the 1920s or 30s. His depression left him catatonic toward the end of his life and he never left that facility. When, 75 years later, I needed psychotropic medication as part of my treatment plan, I thought of him whenever ...
Re v. 07/14 5812 Lisinopril Tablets USP FULL PRESCRIBING
... Lisinopril tablets USP are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These b ...
... Lisinopril tablets USP are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These b ...
Crestor Alone or With ER Niacin
... Rosuvastatin monotherapy clearly produced significantly greater reductions in total cholesterol, non-HDL cholesterol, VLDL cholesterol, and apolipoprotein B than did ER niacin. Both monotherapy groups increased plasma HDL cholesterol and decreased triglyceride levels similarly. Although rosuvastat ...
... Rosuvastatin monotherapy clearly produced significantly greater reductions in total cholesterol, non-HDL cholesterol, VLDL cholesterol, and apolipoprotein B than did ER niacin. Both monotherapy groups increased plasma HDL cholesterol and decreased triglyceride levels similarly. Although rosuvastat ...
2.0 Synopsis
... Although not statistically significantly different, the percentage of placebo subjects with treatmentemergent infectious AEs was greater than that of adalimumab 160/80 mg subjects, indicating that there is no evidence of increased risk of infection with short-term adalimumab therapy. No cases of tub ...
... Although not statistically significantly different, the percentage of placebo subjects with treatmentemergent infectious AEs was greater than that of adalimumab 160/80 mg subjects, indicating that there is no evidence of increased risk of infection with short-term adalimumab therapy. No cases of tub ...
Conscious Sedation:
... Sedation Score 0 = Fully awake Sedation Score 1 = Light sedation, largely aware of self/surroundings. Mildly sleepy. Sedation Score 2 = Moderate sedation, slightly aware of self/surroundings; somnolent but easily ...
... Sedation Score 0 = Fully awake Sedation Score 1 = Light sedation, largely aware of self/surroundings. Mildly sleepy. Sedation Score 2 = Moderate sedation, slightly aware of self/surroundings; somnolent but easily ...
At-Home Dialysis: Consider the Advantages
... Before hemodialysis can begin, a doctor must establish access to the bloodstream via either a fistula or a graft. A fistula is created by surgically connecting an artery to a vein, usually in the forearm; a graft is created by surgically implanting a plastic tube under the skin to join an artery and ...
... Before hemodialysis can begin, a doctor must establish access to the bloodstream via either a fistula or a graft. A fistula is created by surgically connecting an artery to a vein, usually in the forearm; a graft is created by surgically implanting a plastic tube under the skin to join an artery and ...
Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients
... agents for the initial treatment of SE, achieving lasting control in 80% of patients.2,3 Textbooks and expert opinion recommend both diazepam and lorazepam as initial therapy for children in SE and provide recommended doses that are commonly used in practice.4,5 In addition, midazolam has been used ...
... agents for the initial treatment of SE, achieving lasting control in 80% of patients.2,3 Textbooks and expert opinion recommend both diazepam and lorazepam as initial therapy for children in SE and provide recommended doses that are commonly used in practice.4,5 In addition, midazolam has been used ...
187 Formulation and Evaluation of Rofecoxib Tablets
... comply with the USP XXV requirements. From the obtained data in Table (2) the percent of drug contents in ROF tablets were found to be within the range of 99.5 to 102.5%. The values of disintegration time of the prepared ROF tablets are within the allowable range of the USP XXV for uncoated tablets. ...
... comply with the USP XXV requirements. From the obtained data in Table (2) the percent of drug contents in ROF tablets were found to be within the range of 99.5 to 102.5%. The values of disintegration time of the prepared ROF tablets are within the allowable range of the USP XXV for uncoated tablets. ...
praceoryginalne - Wydawnictwo Naukowe UMP
... Release was shown to occur by a diffusion mechanism since the plot of Mt /M ∞ against square root of time was linear up to Mt /M ∞ of about 0.5, i.e. 5 hours. In the case of the 2% loading, equilibration was more or less complete at 2 weeks, and was definitely complete by 3 weeks. The value of relea ...
... Release was shown to occur by a diffusion mechanism since the plot of Mt /M ∞ against square root of time was linear up to Mt /M ∞ of about 0.5, i.e. 5 hours. In the case of the 2% loading, equilibration was more or less complete at 2 weeks, and was definitely complete by 3 weeks. The value of relea ...
Continuous nebulization therapy for asthma with
... has decreased potential side effects because of their selective receptor activity; repeated treatment has been shown to be effective.5–13 Various studies have demonstrated the efficacy and safety of continuous nebulization therapy for delivering aerosols of the b2 agonists terbutaline sulfate or alb ...
... has decreased potential side effects because of their selective receptor activity; repeated treatment has been shown to be effective.5–13 Various studies have demonstrated the efficacy and safety of continuous nebulization therapy for delivering aerosols of the b2 agonists terbutaline sulfate or alb ...
Journal of Legal Medicine The Need for Ibogaine in
... she desperately craves. She knows that she has lost all control and realizes that her addiction may soon take her life, but up against a wall with nowhere to turn, Samantha needs a miracle. What Samantha does not know is that there is a drug that could interrupt her dependency on heroin for long eno ...
... she desperately craves. She knows that she has lost all control and realizes that her addiction may soon take her life, but up against a wall with nowhere to turn, Samantha needs a miracle. What Samantha does not know is that there is a drug that could interrupt her dependency on heroin for long eno ...
DEVELOPMENT AND VALIDATION OF A RP- HPLC METHOD FOR SIMULTANEOUS
... (8,12,16,20,24,28,32) for norfloxacin. The solutions were injected into HPLC system. Each of the concentration was injected in triplicate to get reproducible response. The run time was 14 min and the peak areas were measured. The calibration curve was plotted as concentration of the respective drug ...
... (8,12,16,20,24,28,32) for norfloxacin. The solutions were injected into HPLC system. Each of the concentration was injected in triplicate to get reproducible response. The run time was 14 min and the peak areas were measured. The calibration curve was plotted as concentration of the respective drug ...
A Review on Benzylpiperazine and Trifluoromethylphenypiperazine
... BZP (Campbell, Cline et al. 1973). In a recent research using hooded rats, BZP‟s acute effects was also shown to be that of many similarities to methamphetamine, only that the latter might shown more potency, thus indicating the possible risk for abuse and drug dependence for BZP as in the case of m ...
... BZP (Campbell, Cline et al. 1973). In a recent research using hooded rats, BZP‟s acute effects was also shown to be that of many similarities to methamphetamine, only that the latter might shown more potency, thus indicating the possible risk for abuse and drug dependence for BZP as in the case of m ...
Antidepressants for insomnia
... used long-term for the treatment of insomnia. This was the consensus view of the panel of a 1983 National Institute of Health (NIH 1983) Consensus Conference on the medication treatment of insomnia, which became a guideline for clinical practice in the United States (US). Later the UK Committee on S ...
... used long-term for the treatment of insomnia. This was the consensus view of the panel of a 1983 National Institute of Health (NIH 1983) Consensus Conference on the medication treatment of insomnia, which became a guideline for clinical practice in the United States (US). Later the UK Committee on S ...
the concept of the therapeutic window in the choice of h1
... and cognitive impairment.5 These effects could become an issue in situations in which patients overmedicate beyond the prescribed dose due to inadequate symptom control of either rhinitis or urticaria. GENETIC INFLUENCES Variations in the population and among different racial populations, in terms o ...
... and cognitive impairment.5 These effects could become an issue in situations in which patients overmedicate beyond the prescribed dose due to inadequate symptom control of either rhinitis or urticaria. GENETIC INFLUENCES Variations in the population and among different racial populations, in terms o ...
Renal excretion
... severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Procedure number UK/H/PSUR/0062/0001 ...
... severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Procedure number UK/H/PSUR/0062/0001 ...
Genotoxic impurities
... FDA Draft Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products; Recommended Approaches ...
... FDA Draft Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products; Recommended Approaches ...
December 2014 Coding Queries (PDF 290KB)
... Q: What is the correct procedure code to assign for endovenous radiofrequency ablation (RFA) or endovenous laser therapy (EVLT) for the treatment of varicose veins? A: Endovenous thermal ablation is a new, minimally invasive endovenous technique for the treatment of varicose veins. There are two typ ...
... Q: What is the correct procedure code to assign for endovenous radiofrequency ablation (RFA) or endovenous laser therapy (EVLT) for the treatment of varicose veins? A: Endovenous thermal ablation is a new, minimally invasive endovenous technique for the treatment of varicose veins. There are two typ ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.